Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
2018/11/07 by Vincenzo Mazzaferro, Bassel F. El‐Rayes, Bassel F. El-Rayes +19 · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Cholangiocarcinoma and Gallbladder Cancer Studies #Fibroblast Growth Factor Research #Gastrointestinal Tumor Research and Treatment
paper · pdf · doi:10.1038/s41416-018-0334-0
Abstract
BACKGROUND: Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, has shown preliminary therapeutic activity against FGFR2 fusion-positive iCCA. METHODS: This multicentre, phase 1/2, open-label study enrolled adult patients with unresectable iCCA with FGFR2 fusion, who progressed, were intolerant or not eligible to first-line chemotherapy (NCT01752920). Subjects received derazantinib in continuous daily doses. Tumour response was assessed according to RECIST 1.1 every 8 weeks. RESULTS: Twenty-nine patients (18 women/11 men; median age, 58.7 years), 2 treatment-naive and 27 who progressed after at least one prior systemic therapy, were enrolled. Overall response rate was 20.7%, disease control rate was 82.8%. Estimated median progression-free survival was 5.7 months (95% CI: 4.04-9.2 months). Treatment-related adverse events (AE) were observed in 27 patients (93.1%, all grades), including asthenia/fatigue (69.0%), eye toxicity (41.4%), and hyperphosphatemia (75.9%). Grade ≥ 3 AEs occurred in 8 patients (27.6%). CONCLUSION: Derazantinib demonstrated encouraging anti-tumour activity and a manageable safety profile in patients with advanced, unresectable iCCA with FGFR2 fusion who progressed after chemotherapy. A pivotal trial of derazantinib in iCCA is ongoing (NCT03230318).
Cited by
- Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
- The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors
- New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
- TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. [europepmc]
- Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. [europepmc]
- New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. [europepmc]
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. [europepmc]
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management. [europepmc]
- Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. [europepmc]
- Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. [europepmc]
- Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. [europepmc]
- Therapy of Primary Liver Cancer. [europepmc]
- FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention. [europepmc]
- Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. [europepmc]
- Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. [europepmc]
- Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. [europepmc]
- PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. [europepmc]
- Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. [europepmc]
- FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. [europepmc]
- FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. [europepmc]
- Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study. [europepmc]
- New developments in the biology of fibroblast growth factors. [europepmc]
- FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. [europepmc]
- EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. [europepmc]
- Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. [europepmc]
- FGFR families: biological functions and therapeutic interventions in tumors. [europepmc]
- British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. [europepmc]
- Targeting FGFR for cancer therapy. [europepmc]
Related